Marta Maschio

Prof. Marta Maschio

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2012 in Current Neuropharmacology
Verified
Journal Article
Open access
MMMarta Maschio
Marta Maschio
In patients with brain tumor (BT), seizures are the onset symptom in 20-40% of patients, while a further 20-45% of patients will present them during the course of the disease. These patients present a complex therapeutic profile and require a unique and multidisciplinary approach. The choice of antiepileptic drugs is challenging for this particular patient population because brain tumor-related epilepsy (BTRE) is often drug-resistant, has a strong impact on the quality of life and weighs heavily on public health expenditures.In BT patients, the presence of epilepsy is considered the most important risk factor for long-term disability. For this reason, the problem of the proper administration of medications and their potential side effects is of great importance, because good seizure control can significantly improve the patient's psychological and relational sphere. In these patients, new generation drugs such as gabapentin, lacosamide, levetiracetam, oxcarbazepine, pregabalin, topiramate, zonisamide are preferred because they have fewer drug interactions and cause fewer side effects. Among the recently marketed drugs, lacosamide has demonstrated promising results and should be considered a possible treatment option. Therefore, it is necessary to develop a customized treatment plan for each individual patient with BTRE. This requires a vision of patient management concerned not only with medical therapies (pharmacological, surgical, radiological, etc.) but also with emotional and psychological support for the individual as well as his or her family throughout all stages of the illness.

18 January 2011 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AFAlessandra Fabi
Alessandra Fabi
AFAlessandra Felici
Alessandra Felici
GMGiulio Metro
Giulio Metro
AMAlessandra Mirri
Alessandra Mirri
EBEmilio Bria
Emilio Bria
CCCarmine M Carapella
Carmine M Carapella
To evaluate the therapeutic strategies commonly employed in the clinic for the management of brain metastases (BMs) and to correlate disease outcome with type of treatment and therapeutic resources available at the treating center.

7 December 2018 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
AGAlessandro Galgani
Alessandro Galgani
CPCaterina Palleria
Caterina Palleria
LILuigi Francesco Iannone
Luigi Francesco Iannone
GSGiovambattista De Sarro
Giovambattista De Sarro
FGFilippo Sean Giorgi
Filippo Sean Giorgi
EREmilio Russo
Emilio Russo
Direct oral anticoagulants (DOACs), namely apixaban, dabigatran, edoxaban, and rivaroxaban are being increasingly prescribed among the general population, as they are considered to be associated to lower bleeding risk than classical anticoagulants, and do not require coagulation monitoring. Likewise, DOACs are increasingly concomitantly prescribed in patients with epilepsy taking, therefore, antiepileptic drugs (AEDs), above all among the elderly. As a result, potential interactions may cause an increased risk of DOAC-related bleeding or a reduced antithrombotic efficacy. The objective of the present review is to describe the pharmacokinetic interactions between AEDs and DOACs of clinical relevance. We observed that there are only few clinical reports in which such interactions have been described in patients. More data are available on the pharmacokinetics of both drugs classes which allow speculating on their potential interactions. Older AEDs, acting on cytochrome P450 isoenzymes, and especially on CYP3A4, such as phenobarbital, phenytoin, and carbamazepine are more likely to significantly reduce the anticoagulant effect of DOACs (especially rivaroxaban, apixaban, and edoxaban). Newer AEDs not affecting significantly CYP or P-gp, such as lamotrigine, or pregabalin are not likely to affect DOACs efficacy. Zonisamide and lacosamide, which do not affect significantly CYP activity in vitro, might have a quite safe profile, even though their effects on P-gp are not well-known, yet. Levetiracetam exerts only a potential effect on P-gp activity, and thus it might be safe, as well. In conclusion, there are only few case reports and limited evidence on interactions between DOACs and AEDs in patients. However, the overall evidence suggests that the interaction between these drug classes might be of high clinical relevance and therefore further studies in larger patients' cohorts are warranted for the future in order to better clarify their pharmacokinetic and define the most appropriate clinical behavior.

25 November 2010 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
MMMarta Maschio
Marta Maschio
LDLoredana Dinapoli
Loredana Dinapoli
FSFrancesca Sperati
Francesca Sperati
APAndrea Pace
Andrea Pace
AFAlessandra Fabi
Alessandra Fabi
PMPaola Muti
Paola Muti

1 June 1997 in Epilepsia
Verified
Journal Article
Closed access
PDF file
GGGian Luigi Gigli
Gian Luigi Gigli
FPFabio Placidi
Fabio Placidi
MDMarina Diomedi
Marina Diomedi
MMMarta Maschio
Marta Maschio
GSGiulia Silvestri
Giulia Silvestri
MMMaria Grazia Marciani
Maria Grazia Marciani

10 May 2006 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
MMMarta Maschio
Marta Maschio
FAFiorenzo Albani
Fiorenzo Albani
ABAgostino Baruzzi
Agostino Baruzzi
AZAlessia Zarabla
Alessia Zarabla
LDLoredana Dinapoli
Loredana Dinapoli
BJBruno Jandolo
Bruno Jandolo